Amgen Intervenes in Regeneron v. Mylan BPCIA Aflibercept Litigation to Seek Public Access to Sealed Documents
New Patents Listed in the Purple Book for Regeneron’s EYLEA
Regeneron v. Mylan – Update on Aflibercept BPCIA Litigation
Aflibercept IPRs Update
FDA Approves Amgen’s RIABNI™ (Rituximab-arrx) for Adults With Moderate to Severe Rheumatoid Arthritis
Regeneron’s Disclaimer of Aflibercept Formulation Patent Causes PTAB Denial of Institution of Celltrion PGR
Celltrion Announces Agreement with Brazilian Government to Supply Infliximab Biosimilar
Coherus and Xbrane Announce Acceptance of Regulatory Submissions for Ranibizumab Biosimilars
Sanofi Files Opposition to Amgen’s Petition for Federal Circuit to Reconsider Decision Invalidating Praluent Patents
Subscribe: Subscribe via RSS
Blogs
Firm/Org